Advertisement
Financing › Details
PhagoMed–SEVERAL: investment, 201906 2nd financing round €1.5m from existing + new investors
Period | 2019-06-27 | |
Predecessor | PhagoMed–SEVERAL: investment, 201808 seed financing round €1.55m from private investors + aws | |
Money taker | PhagoMed Biopharma GmbH | |
Today | BioNTech R&D (Austria) GmbH | |
Group | BioNTech (Group) | |
Money source | SEVERAL | |
Product | phage therapy | |
Product 2 | venture capital | |
PhagoMed Biopharma GmbH. (6/27/19). "Press Release: Further Investment for PhagoMed. Investors Support Phage Therapy". Vienna.
> Novel Approach to Solve The Antibiotics Crisis Receives Further Millions
Austrian biotech company PhagoMed Biopharma GmbH successfully completed another financing round. PhagoMed, located at the Vienna Biocenter, is focused on developing virus-(phage-) based therapies against drug-resistant and chronic bacterial infections. Investors provided further €1.5 million in equity investments to support this novel approach to tackle the antibiotics crisis. The additional funding will be used to accelerate three in-house development programs.
PhagoMed Biopharma GmbH (PhagoMed) works on solutions for the global antibiotics crisis – the increasing rate of multi-drug resistances against the historically so effective antibiotics. The company develops pharmaceuticals based on natural viruses, called phages, that can infect and destroy bacteria. Phages and phage-based pharmaceuticals therefore have the potential to become a highly effective alternative to antibiotics for the treatment of multi-drug resistant infections. Indeed, PhagoMed’s co-founders have successfully treated individual patients with phages in Germany – as a last resort when antibiotics had failed.
Already in 2018 PhagoMed successfully raised more than €4 million in public grants and private investments and set-up its research programs at the Vienna Biocenter. The company today announced further investments from existing and new investors totaling €1.5 million.
„Our research activities over the past year led to the identification of a series of drug candidates, the first of which are now being validated in animal trials. These results convinced both our existing and new investors to support our R&D activities with further equity investments.” says Alexander Belcredi, Co-Founder and Co-CEO of PhagoMed. „These additional seed investments will allow us to further increase the research team in Vienna and to selectively invest into our infrastructure.”
One specific field of focus for the company is the treatment of infected artificial joints, such as hip prostheses. These widespread infections are difficult to treat since they are often caused by multi-drug resistant bacteria. In addition, these bacteria typically form a biofilm on the surface of the prosthesis, which further reduces the effectiveness of antibiotics. In these types of complex infections phages are especially promising as a treatment alternative since they can degrade the bacterial biofilms as well as kill the multi-drug resistant bacteria. One of the potent drug candidates identified by PhagoMed is specifically aimed at these infections and is now being validated in animal trials. PhagoMed plans to start a first clinical trial in this indication by 2021.
Record changed: 2024-01-09 |
Advertisement
More documents for BioNTech (Group)
- [1] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
- [2] BioNTech SE. (2/8/24). "Press Release: BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs". Mainz & London....
- [3] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
- [4] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
- [5] WuXi Biologics. (1/11/24). "Press Release: WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates". Shanghai....
- [6] BioNTech SE. (1/9/24). "Press Release: BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference". Mainz....
- [7] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
- [8] BioNTech SE. (12/18/23). "Press Release: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda". Kigali....
- [9] Biotheus Inc.. (11/6/23). "Press Release: Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications". Zhuhai....
- [10] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top